{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:40:14Z","timestamp":1772134814491,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-072678"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-007274"],"award-info":[{"award-number":["POCI-01-0145-FEDER-007274"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000029"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000029"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-072678"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-072678"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-072678"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-072678"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-072678"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-072678"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-072678"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-072678"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gilead Sciences Portugal Associa\u00e7\u00e3o Portuguesa Contra a Leucemia, Portugal Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia, Portugal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41375-024-02446-w","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T11:01:57Z","timestamp":1729854117000},"page":"178-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8625-5420","authenticated-orcid":false,"given":"Jo\u00e3o L.","family":"Pereira","sequence":"first","affiliation":[]},{"given":"Liliana","family":"Arede","sequence":"additional","affiliation":[]},{"given":"Francisca","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Matos","sequence":"additional","affiliation":[]},{"given":"Dulcineia","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Rita F.","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Alexandre M.","family":"Carmo","sequence":"additional","affiliation":[]},{"given":"Maria J.","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 C.","family":"Machado","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3476-0211","authenticated-orcid":false,"given":"Delfim","family":"Duarte","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7347-2592","authenticated-orcid":false,"given":"Nuno R.","family":"dos Santos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"2446_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390:298\u2013310.","journal-title":"Lancet"},{"key":"2446_CR2","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ajh.25071","volume":"93","author":"SM Ansell","year":"2018","unstructured":"Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93:704\u201315.","journal-title":"Am J Hematol"},{"key":"2446_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejca.2017.08.014","volume":"85","author":"JM Michot","year":"2017","unstructured":"Michot JM, Lazarovici J, Ghez D, Danu A, Ferm\u00e9 C, Bigorgne A, et al. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma. Eur J Cancer. 2017;85:67\u201377.","journal-title":"Eur J Cancer"},{"key":"2446_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1182\/asheducation-2016.1.390","volume":"2016","author":"P Lulla","year":"2016","unstructured":"Lulla P, Heslop HE. Checkpoint inhibition and cellular immunotherapy in lymphoma. Hematol Am Soc Hematol Educ Program. 2016;2016:390\u20136.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2446_CR5","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1182\/bloodadvances.2017012534","volume":"1","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Armand P, Wright KT, Rodig SJ. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017;1:2643\u201354.","journal-title":"Blood Adv"},{"key":"2446_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11864-016-0401-9","volume":"17","author":"E Matsuki","year":"2016","unstructured":"Matsuki E, Younes A. Checkpoint inhibitors and other immune therapies for Hodgkin and non-Hodgkin lymphoma. Curr Treat Options Oncol. 2016;17:31.","journal-title":"Curr Treat Options Oncol"},{"key":"2446_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood.2019000847","volume":"135","author":"J Kline","year":"2020","unstructured":"Kline J, Godfrey J, Ansell SM. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020;135:523\u201333.","journal-title":"Blood"},{"key":"2446_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.14740\/wjon1388","volume":"12","author":"K Tarekegn","year":"2021","unstructured":"Tarekegn K, Ramosa AC, Singh B, Sequeira Grossa HG, Gupta S. Checkpoint Inhibitors in relapsed\/refractory classical Hodgkin lymphoma. World J Oncol. 2021;12:51\u20134.","journal-title":"World J Oncol"},{"key":"2446_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","volume":"15","author":"W Xie","year":"2020","unstructured":"Xie W, Medeiros LJ, Li S, Yin CC, Khoury JD, Xu J. PD-1\/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas. Curr Hematol Malig Rep. 2020;15:372\u201381.","journal-title":"Curr Hematol Malig Rep"},{"key":"2446_CR10","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3390\/biomedicines11061720","volume":"11","author":"S Perdikis-Prati","year":"2023","unstructured":"Perdikis-Prati S, Sheikh S, Bouroumeau A, Lang N. Efficacy of immune checkpoint blockade and biomarkers of response in lymphoma: a narrative review. Biomedicines. 2023;11:1720.","journal-title":"Biomedicines"},{"key":"2446_CR11","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1016\/S1470-2045(15)70103-8","volume":"16","author":"EA Hawkes","year":"2015","unstructured":"Hawkes EA, Grigg A, Chong G. Programmed cell death-1 inhibition in lymphoma. Lancet Oncol. 2015;16:e234\u201345.","journal-title":"Lancet Oncol"},{"key":"2446_CR12","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","volume":"17","author":"DJ Andorsky","year":"2011","unstructured":"Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232\u201344.","journal-title":"Clin Cancer Res"},{"key":"2446_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1083\/jcb.118.2.445","volume":"118","author":"KL Moore","year":"1992","unstructured":"Moore KL, Stults NL, Diaz S, Smith DF, Cummings RD, Varki A, et al. Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. J Cell Biol. 1992;118:445\u201356.","journal-title":"J Cell Biol"},{"key":"2446_CR14","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1182\/blood.V88.7.2415.bloodjournal8872415","volume":"88","author":"DA Guyer","year":"1996","unstructured":"Guyer DA, Moore KL, Lynam EB, Schammel CMG, Rogelj S, McEver RP, et al. P-selectin glycoprotein ligand-1 (PSGL-1) is a ligand for L-selectin in neutrophil aggregation. Blood. 1996;88:2415\u201321.","journal-title":"Blood"},{"key":"2446_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1083\/jcb.128.4.661","volume":"128","author":"KL Moore","year":"1995","unstructured":"Moore KL, Patel KD, Bruehl RE, Fugang L, Johnson DA, Lichenstein HS, et al. P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. J Cell Biol. 1995;128:661\u201371.","journal-title":"J Cell Biol"},{"key":"2446_CR16","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1182\/blood.V88.8.3010.bloodjournal8883010","volume":"88","author":"Z Laszik","year":"1996","unstructured":"Laszik Z, Jansen P, Cummings R, Tedder T, McEver R, Moore K. P-selectin glycoprotein ligand-1 is broadly expressed in cells of myeloid, lymphoid, and dendritic lineage and in some nonhematopoietic cells. Blood. 1996;88:3010\u201321.","journal-title":"Blood"},{"key":"2446_CR17","doi-asserted-by":"publisher","first-page":"22677","DOI":"10.1074\/jbc.270.39.22677","volume":"270","author":"PP Wilkins","year":"1995","unstructured":"Wilkins PP, Moore KL, McEver RP, Cummings RD. Tyrosine sulfation of P-selectin glycoprotein ligand-1 is required for high affinity binding to P-selectin. J Biol Chem. 1995;270:22677\u201380.","journal-title":"J Biol Chem"},{"key":"2446_CR18","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1172\/JCI118888","volume":"98","author":"B Walcheck","year":"1996","unstructured":"Walcheck B, Moore KL, McEver RP, Kishimoto TK. Neutrophil-neutrophil interactions under hydrodynamic shear stress involve L-selectin and PSGL-1: A mechanism that amplifies initial leukocyte accumulation on P-selectin in vitro. J Clin Invest. 1996;98:1081\u20137.","journal-title":"J Clin Invest"},{"key":"2446_CR19","doi-asserted-by":"publisher","first-page":"28786","DOI":"10.1074\/jbc.272.45.28786","volume":"272","author":"E Borges","year":"1997","unstructured":"Borges E, Pendl G, Eytner R, Steegmaier M, Z\u00f6llner O, Vestweber D. The binding of T cell-expressed P-selectin glycoprotein ligand-1 to E- and P-selectin is differentially regulated. J Biol Chem. 1997;272:28786\u201392.","journal-title":"J Biol Chem"},{"key":"2446_CR20","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1074\/jbc.M410899200","volume":"280","author":"M Martinez","year":"2005","unstructured":"Martinez M, Joffraud M, Giraud S, Ba\u00efsse B, Bernimoulin MP, Schapira M, et al. Regulation of PSGL-1 interactions with L-selectin, P-selectin, and E-selectin: role of human fucosyltransferase-IV and -VII. J Biol Chem. 2005;280:5378\u201390.","journal-title":"J Biol Chem"},{"key":"2446_CR21","doi-asserted-by":"publisher","first-page":"7204","DOI":"10.4049\/jimmunol.0902173","volume":"183","author":"M Matsumoto","year":"2009","unstructured":"Matsumoto M, Miyasaka M, Hirata T. P-selectin glycoprotein ligand-1 negatively regulates T-cell immune responses. J Immunol. 2009;183:7204\u201311.","journal-title":"J Immunol"},{"key":"2446_CR22","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.4049\/jimmunol.1103026","volume":"188","author":"KM Veerman","year":"2012","unstructured":"Veerman KM, Carlow DA, Shanina I, Priatel JJ, Horwitz MS, Ziltener HJ. PSGL-1 regulates the migration and proliferation of CD8+ T cells under homeostatic conditions. J Immunol. 2012;188:1638\u201346.","journal-title":"J Immunol"},{"key":"2446_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457\u201395.","journal-title":"Annu Rev Immunol"},{"key":"2446_CR24","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.immuni.2016.04.015","volume":"44","author":"R Tinoco","year":"2016","unstructured":"Tinoco R, Carrette F, Barraza ML, Otero DC, Maga\u00f1a J, Bosenberg MW, et al. PSGL-1 Is an immune checkpoint regulator that promotes T cell exhaustion. Immunity. 2016;44:1190\u2013203.","journal-title":"Immunity"},{"key":"2446_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.677824","volume":"12","author":"R Tinoco","year":"2021","unstructured":"Tinoco R, Neubert EN, Stairiker CJ, Henriquez ML, Bradley LM. PSGL-1 is a T cell intrinsic inhibitor that regulates effector and memory differentiation and responses during viral infection. Front Immunol. 2021;12:677824.","journal-title":"Front Immunol"},{"key":"2446_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.869768","volume":"13","author":"KM Viramontes","year":"2022","unstructured":"Viramontes KM, Neubert EN, DeRogatis JM, Tinoco R. PD-1 immune checkpoint blockade and PSGL-1 inhibition synergize to reinvigorate exhausted T cells. Front Immunol. 2022;13:869768.","journal-title":"Front Immunol"},{"key":"2446_CR27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1158\/2326-6066.CIR-21-0690","volume":"10","author":"JM DeRogatis","year":"2022","unstructured":"DeRogatis JM, Viramontes KM, Neubert EN, Henriquez ML, Guerrero-Juarez CF, Tinoco R. Targeting the PSGL-1 immune checkpoint promotes immunity to PD-1\u2013resistant melanoma. Cancer Immunol Res. 2022;10:612\u201325.","journal-title":"Cancer Immunol Res"},{"key":"2446_CR28","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1158\/2767-9764.CRC-22-0513","volume":"3","author":"K Kauffman","year":"2023","unstructured":"Kauffman K, Manfra D, Nowakowska D, Zafari M, Nguyen PA, Phennicie R, et al. PSGL-1 blockade induces classical activation of human tumor-associated macrophages. Cancer Res Commun. 2023;3:2182\u201394.","journal-title":"Cancer Res Commun"},{"key":"2446_CR29","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1084\/jem.190.12.1769","volume":"190","author":"J Yang","year":"1999","unstructured":"Yang J, Hirata T, Croce K, Merrill-Skoloff G, Tchernychev B, Williams E, et al. Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration. J Exp Med. 1999;190:1769\u201382.","journal-title":"J Exp Med"},{"key":"2446_CR30","doi-asserted-by":"publisher","first-page":"W242","DOI":"10.1093\/nar\/gky354","volume":"46","author":"JP Concordet","year":"2018","unstructured":"Concordet JP, Haeussler M. CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens. Nucleic Acids Res. 2018;46:W242\u20135.","journal-title":"Nucleic Acids Res"},{"key":"2446_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100719","volume":"2","author":"E Eremenko","year":"2021","unstructured":"Eremenko E, Taylor ZV, Khand B, Zaccai S, Porgador A, Monsonego A. An optimized protocol for the retroviral transduction of mouse CD4 T cells. STAR Protoc. 2021;2:100719.","journal-title":"STAR Protoc"},{"key":"2446_CR32","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 2010;116:3875\u201386.","journal-title":"Blood"},{"key":"2446_CR33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nri1330","volume":"4","author":"RT Abraham","year":"2004","unstructured":"Abraham RT, Weiss A. Jurkat T cells and development of the T-cell receptor signalling paradigm. Nat Rev Immunol. 2004;4:301\u20138.","journal-title":"Nat Rev Immunol"},{"key":"2446_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112436","volume":"42","author":"JL Hope","year":"2023","unstructured":"Hope JL, Otero DC, Bae EA, Stairiker CJ, Palete AB, Faso HA, et al. PSGL-1 attenuates early TCR signaling to suppress CD8+ T cell progenitor differentiation and elicit terminal CD8+ T cell exhaustion. Cell Rep. 2023;42:112436.","journal-title":"Cell Rep"},{"key":"2446_CR35","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1189\/jlb.72.3.470","volume":"72","author":"A Thatte","year":"2002","unstructured":"Thatte A, Ficarro S, Snapp KR, Wild MK, Vestweber D, Hunt DF, et al. Binding of function-blocking mAbs to mouse and human P-selectin glycoprotein ligand-1 peptides with and without tyrosine sulfation. J Leukoc Biol. 2002;72:470\u20137.","journal-title":"J Leukoc Biol"},{"key":"2446_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101125","volume":"14","author":"JL Pereira","year":"2021","unstructured":"Pereira JL, Cavaco P, da Silva RC, Pacheco-Leyva I, Mereiter S, Pinto R, et al. P-selectin glycoprotein ligand 1 promotes T cell lymphoma development and dissemination. Transl Oncol. 2021;14:101125.","journal-title":"Transl Oncol"},{"key":"2446_CR37","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1182\/bloodadvances.2017004382","volume":"1","author":"NA Bezman","year":"2017","unstructured":"Bezman NA, Jhatakia A, Kearney AY, Brender T, Maurer M, Henning K, et al. PD-1 blockade enhances elotuzumab efficacy in mouse tumor models. Blood Adv. 2017;1:753\u201365.","journal-title":"Blood Adv"},{"key":"2446_CR38","doi-asserted-by":"publisher","first-page":"e61338","DOI":"10.1371\/journal.pone.0061338","volume":"8","author":"ML Davila","year":"2013","unstructured":"Davila ML, Kloss CC, Gunset G, Sadelain M. CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS ONE. 2013;8:e61338.","journal-title":"PLoS ONE"},{"key":"2446_CR39","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.mad.2005.11.001","volume":"127","author":"P Saule","year":"2006","unstructured":"Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M. Accumulation of memory T cells from childhood to old age: Central and effector memory cells in CD4+ versus effector memory and terminally differentiated memory cells in CD8+ compartment. Mech Ageing Dev. 2006;127:274\u201381.","journal-title":"Mech Ageing Dev"},{"key":"2446_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3257","volume":"42","author":"JL Pereira","year":"2024","unstructured":"Pereira JL, Ferreira F, dos Santos NR. Antibody targeting of surface P\u2010selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition. Hematol Oncol. 2024;42:e3257.","journal-title":"Hematol Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02446-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02446-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02446-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T06:04:42Z","timestamp":1736402682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02446-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2446"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02446-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4018077\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"5 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Mouse experimental procedures were approved by the i3S ethics committee (approval no. 15\/CECRI\/2020) and Portuguese authorities (<i>Dire\u00e7\u00e3o-Geral de Agricultura e Veterin\u00e1ria<\/i>; ref. no. 421\/000\/000\/2021) and followed European and Portuguese guidelines (Directive 2010\/63\/EU and decree laws no. 113\/2013 and 1\/2019). Peripheral blood was provided by the S\u00e3o Jo\u00e3o University Medical Centre blood bank after ethical approval (ref. no. 398\/2020). Lymphoma biopsies were obtained at the Onco-Hematology Department of Portuguese Oncology Institute (Porto) after ethical approval (ref. GOM_PI_2013.03). Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}